Sponsored Product Theaters
2024 NON-AAOA SATELLITE EVENTS
These commercially supported Product Theaters are independent of the American Academy of Otolaryngic Allergy (AAOA) educational activities and are not accredited by AAOA.
2024 AAOA ANNUAL MEETING
GSK
What’s Driving Recurrent Disease in Your Patients?
Targeting Eosinophils With NUCALA as an Option for Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Saturday, November 9th 7.00 AM – 8.00 AM
Location: Four Seasons Hotel Las Vegas @ Four Seasons Ballroom 4
Sanofi And Regeneron
Saturday, November 9th 11.55 AM – 12.55 PM
Location: Four Seasons Hotel Las Vegas @ Four Seasons Ballroom 4
AstraZeneca
Addressing Eosinophilic Inflammation: A Targeted Treatment Approach
Sunday, November 10th 7.00 AM – 8.00 AM
Location: Four Seasons Hotel Las Vegas @ Four Seasons Ballroom 4
2024 AAOA advanced COURSE IN ALLERGY & IMMUNOLOGY
Sanofi And Regeneron
2024 AAOA BASIC COURSE IN ALLERGY & IMMUNOLOGY
Sanofi And Regeneron – Residents Only
TYPE 2 INFLAMMATION IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (CRSwNP)
Friday July 26th 7.00-8.00 AM
Location: The Diplomat, Hollywood, FL @ 320
Stand-Alone CME Symposium
CLINICAL USE OF BIOLOGICS FOR CRSWNP: IMPLEMENTING STRATEGIES FOR TREATMENT SUCCESS
Thursday, September 12, 2024
7:00 PM – 8:00 PM EDT
6:00 PM – 7:00 PM CDT
4:00 PM – 5:00 PM PDT
Space is limited – CLICK HERE to register!
PROGRAM OVERVIEW
During this case-based interactive symposium, our esteemed faculty will discuss strategies to improve the care of patients with patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Key topics will include patient evaluation, selection criteria for surgical or biologic treatment, and current evidence on comparative safety and efficacy of available treatments.
This educational activity has been designed for allergists, otolaryngologists, nurse practitioners, and physician assistants involved in the management of patients with CRSwNP.
LEARNING OBJECTIVES
Upon completion of this educational activity, participants should be able to:
- Effectively assess severity in patients with CRSwNP
- Select appropriate biologic or surgical treatment options for patients with CRSwNP based on available efficacy and safety data
- Implement strategies for the effective use of biologic therapies in the treatment of appropriate patients with CRSwNP and to overcome barriers to successful treatment
Faculty Presenters:
Christine Franzese, MD and Joseph K. Han, MD
This activity has been approved for AMA PRA Category 1 Credit™.
This activity is provided by Integrity CE, LLC.
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals,
Inc and Sanofi.
These commercially supported Product Theaters are independent of the American Academy of Otolaryngic Allergy (AAOA) educational activities and are not accredited by AAOA.